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INTRODUCTION
Normal mammalian cells exhibit a limited proliferative potential (1) . At the end of their replicative span, these cells senesce, becoming enlarged, vacuolated and flattened. These cells are metabolically active but are in a state of irreversible Gl arrest and do not divide (2) (3) (4) . Cellular senescence is a genetically programmed event which is controlled by genes whose collective effect manifests at the end of the cell's life span. In contrast to normal cells, breast cancer and other tumor cells can multiply indefinitely, having escaped senescence as a result of alterations of critical genes (5, 6, 7) . Escape from senescence thus represents an important step in tumor progression. Since senescence genes are involved in negative regulation of cell growth, they are regarded as a class of tumor suppressor genes. The main focus of this project is identification, localization and high resolution mapping of the gene(s) involved in the restoration of senescence to immortal breast tumor cells.
Cytogenetic and loss of heterozygosity (LOH) studies on breast tumors suggest the presence of tumor suppressor genes on human chromosomes 1, 3, 6, 11, 13, 16, 17, 19 and 20 (8,9,10) . Increased frequency of LOH and chromosomal deletions on the long arm of human chromosome 16 at 16q22, 16q24 and 16q24-qter has been reported in breast cancer, prostate cancer and hepatocellular carcinoma (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . These data suggest an important role for a gene(s) on chromosome 16 during the conversion of normal breast epithelium into a cancerous state.
PREVIOUS WORK
To determine the effect of the introduction of normal human chromosome 16 into breast cancer cells, intact normal human chromosome 16 was introduced into human and rat mammary carcinoma cells by means of microcell mediated chromosome transfer method (MMCT). Human breast cancer cell lines SKBR-3 and MCF7 and rat mammary tumor cell lines NMU and LA7 were used in these experiments. Chromosome transfer clones showed morphological and growth characteristics typical to senescent cells. Continuous cultivation of the senescent cells in selection media gave rise to revertant clones which are morphologically similar to and have the same growth rate as the immortal parent cells. These revertant clones were shown to have lost the region of the introduced human DNA that was capable of restoring senescence to the tumor cells. PCR analysis of 5 human revertants for the presence of previously mapped polymorphic chromosome 16 specific markers localized the senescence gene to the long arm of chromosome 16. Transfer of human chromosome 13 into MCF7 and NMU and transfer of human chromosome 7 into LA7 did not restore senescence to these cells.
A sub-monochromosomal hybrid library developed in Dr. Athwal's lab consists of mouse A9 cells that contain fragments of human chromosome 16 tagged with the gpt selectable marker. Nine hybrid clones containing fragments of human chromosome 16 were analyzed cytogenetically and by PCR using previously mapped chromosome 16 markers to determine the size and position of the fragment on chromosome 16. Two fragments of chromosome 16 containing regions 16q22-qter and 16q23-qter were selected for further chromosome transfer studies.
Introduction of these fragments of chromosome 16, containing either the region 16q22-qter or 16q23-qter also induced senescence in both the human and rat breast tumor cells.The same phenotype was observed in several independent experiments. Furthermore, these fragments induced senescence in ovarian cancer cells and in SV40 transformed human and mouse fibroblast cells. These results confirm the involvement of 16q22-qter in restoration of senescence to immortal tumor cells by functional complementation.
J
Deepthi E. Redd) Initial analysis of five rat (mammary tumor) revertant clones with fifteen chromosome 16 specific markers had localized the senescence gene to 16q24. 2-16q24.3 . Further analysis with 30 rat revertants using an additional 60 markers from 16q23-qter was done. A consensus deletion map was derived from the presence or the absence of these markers in the revertant clones. This consensus deletion region contains 21 markers. Based on information from genetic and physical maps of these markers available from various databases, we mapped the region of the senescence gene (SEN 16) to a 3-7 cM region at 16q24.3.
The remaining fragment of chromosome 16q23-qter present in a rat revertant clone of LA7 which lost the region of the chromosome that harbored the senescence gene, was transferred into the human breast tumor cell line, MCF7. This fragment of human DNA did not restore senescence to the human breast tumor cells. These results indicate that the same region of chromosome 16, perhaps the same gene at 16q24.3, restores senescence in both rat and human immortal tumor cells.
To further localize SEN 16, a partial YAC contig was assembled corresponding to the 3-7 cM region at 16q24.3 and analyzed for marker content. A 360 kb YAC from this contig, 792t2, was found to restore senescence to rat and human mammary tumor cells, and, to rat ovarian tumor cells.
BODY EXPERIMENTAL METHODS

Cell Lines and Growth Conditions
The cell lines used are human breast tumor cell line, MCF7, (ATCC); rat mammary tumor cell line LA7 (22); and, mouse immortal epithelial cell line, A9 (ATCC). All cultured were maintained in DF12 medium supplemented with 10-15% FBS at 37»C in 7.5% CO 2 incubators. YAC transfer clones are grown in 400 (Xg/ml of G418 containing media.
Growth of BAC Clones
All BAC clones were grown in LB medium (Sigma) containing 20 |ig/ml chloramphenicol (Sigma). Retrofitted BAC clones were grown in LB medium containing 20 |0.g/ml chloramphenicol and 30 |ig/ml of kanamycin (Sigma).
Isolation of BAC DNA (mini-prep)
To isolate BAC DNA from small culture volumes, a standard mini-prep protocol was used (protocol from Research Genetics, Huntsville, AL). Briefly, a BAC clone was grown overnight at 37 °C in 1.5 ml LB medium containing 20 U.g/ml of chloramphenicol (and 30 U-g/ml of kanamycin where necessary). Cells were harvested at high speed and the pellet was resuspended in 100 u.1 of solution I containing 50 mM glucose, 20 mM Tris-Cl, pH 8.0, 10 mM EDTA, pH 8.0. 200 ul of freshly prepared solution II containing 0.2 N NaOH, 1% SDS was then added, the contents were mixed and the tube was placed on ice for 1-2 minutes. Next, 150 u,l of potassium acetate (contains 3 M potassium and 5 M acetate) was added to the reaction mixture. The contents were spun down at full speed for 6 minutes in a microcentrifuge at room temperature. The supernatant was then transferred into a fresh tube and the DNA was precipitated with 1 ml of ethanol. The pellet was then washed several times in 70% ethanol, dried and dissolved in 20 |il of TE buffer.
Isolation of BAC DNA (maxi-prep)
To isolate large quantities of BAC DNA, the QIAGEN Maxi protocol was followed. The BAC clone was first grown in 5 ml LB medium containing the appropriate antibiotic and 0.5 ml of this preculture was inoculated into 100 ml LB medium containing the antibiotic(s). The culture was grown at 37 °C for 14 hours with vigorous shaking. Cells were then harvested by centrifugation in 50 ml tubes and resuspended in 10 ml of buffer PI containing 100 |xg/ml RNase A, 50 mM Tris-Cl, pH 8.0, 10 mM EDTA. Next 10 ml of lysis buffer P2 containing 200 mM NaOH and 1% SDS was added. The contents were mixed gently and incubated at room temperature for 5 minutes. Next, 10 ml of chilled neutralization buffer P3 containing 3 M potassium acetate, pH 5.5 was added. The contents were mixed gently, incubated on ice for 15 minutes, and spun down at 20,000 x g for 30 minutes at 4 °C. The supernatant was removed into fresh tubes and the solution was re-centrifuged at 20,000 x g for another 15 minutes at 4 °C. The supernatant was then applied to a QIAGEN-tip 100 equilibrated with 4 ml of QBT buffer (750 mM NaCl, 50 mM MOPS, pH 7.4, 15% isopropanol and 0.15% Triton-X 100) and the column was allowed to empty by gravity. The tip was then washed with 2 x 10 ml QC wash buffer (1 M NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol). The DNA was then eluted with 5 aliquots of 1 ml QF elution buffer (1.25 M NaCl, 50 mM Tris-Cl, pH 8.5 and 15% isopropanol), prewarmed to 65 °C. The BAC DNA was then precipitated by adding 3.5 ml of room-temperature isopropanol to the eluted DNA and mixing gently. The contents were centrifuged at 15000 x g for 30 minutes at 4 °C. The pellet was washed in 2 ml of 70% ethanol, air-dried and redissolved in TE, pH 8.0. Yield of BAC DNA from this prep was typically 20-40 (Xg from a 100 ml BAC culture.
Restriction Enzyme Digestion of BAC DNA
BAC inserts wee excised from the vector using the restriction enzyme Not I (New England Biolabs). 1 |lg of BAC DNA was digested with Not I restriction enzyme in NEBuffer 3 supplemented with 100 Ug/ml BSA. Complete Not I digestion released the genomic insert and was visualized by separating the digested fragments by PFGE.
For comparison of the restriction enzyme digestion patterns between two BAC clones. DNA digested with Hind III restriction enzyme in buffer E at 37 °C and separated on a 1 % agarose gel containing ethidium bromide.
Pulsed Field Gel Electrophoresis
PFGE of BAC DNA was performed with the CHEF Mapper system from Bio-Rad. The digested DNA was separated on a 1% SeaKem GTG agarose gel using 0.5X standard TBE buffer at 14 °C. The MidRange IIPFG Marker (NEB) was used as the DNA size standard. The gels were run at 200V (6 V/cm approximately), with a pulse angle of 120° and a pulse time of 5-15 seconds. Gels were stained in 0.5 X TBE buffer with 0.2 |ig/ml ethidium bromide for 45 minutes or more with gentle shaking and photographed on a UV transilluminator.
RESULTS AND DISCUSSION
Screening of a BAC Library for Clones Spanning the Consensus Deletion Region
Two approaches were used to identify BACs carrying markers from the consensus deletion region at 16q24.3. A PCR based BAC library, obtained from Research Genetics (Huntsville) was screened using PCR primers for markers in the consensus deletion region. Some of the markers analyzed did not yield any positive clones in this library screen. For most of these markers, BAC ^y / * Deepthi E. Redd) clones were identified using information from the Caltech database. This eliminated the time consuming process of screening other libraries for identification of positive B AC clones for the non-informative markers.
The primer pairs used to screen the BAC library are D16S413, 498, 520, 2750, 2801, 3037, 3048, 3061, 3063, 3077, WI-15838, 12410 and EST00889 . No positive BAC clones were obtained with the primers D16S498, 520, 2801, 3077, WI-15838 and EST00889. However, the markers D16S413, 2750, 3037, 3048, 3061, 3063 and WI-12410 , were informative in obtaining BAC addresses. The corresponding BACs for these markers were purchased from Research Genetics and marker content verified by PCR.
The Human Genome Project at Caltech is involved in isolation and sequencing of YAC, PI and BAC clones from chromosome 16. Search of their database (www.tree.caltech.edu) identified several BAC clones carrying markers from the long arm of chromosome 16. Using this information, BAC clones corresponding to the primer pairs, D16S305, 413, 449, 476, 486, 498, 2727,2733, 2772, 2801 and 2866, were identified. All of these BAC clones were purchased from Research Genetics.
DNA from each of the BAC clones described above was analyzed to confirm the presence of the markers that were used to identify the BAC during screening. Next, these clones were analyzed by PFGE to determine the size of the human DNA inserts and to identify internal Not I sites.
BAC clones were assembled in a contig corresponding to the retrofitted YAC 792t2 which was shown in earlier studies to induce senescence in breast tumor cell lines ( Figure 1 ). In addition, partial contigs of the consensus deletion region at 16q24.3 were created using marker content information. The BAC clones present in these contigs are 440F1 (D16S3037, 3061), 41 1M22 (D16S3063, 3048), 411M24 (D16S3063, 3048), 346J21 (D16S3063, 3048, Wl-12410, 15838), 344A17 (D16S3048, WI-12410, 15838, TIGRA001Y26, SHGC3238, StSG4762, SGC36958), 344B17 (D16S3048, WI-12410, 15838, TIGRA001Y26, SHGC3238, StSG4762, SGC36958),
and 696H9 (D16S2727). No BAC clones containing the markers form the consensus deletion, D16S520, 3077, WI-3661 and 16080 were identified. Based on some of the above information, markers were arranged to construct a map of the region 16q24.3. These assignments are reflected in Figure 19 .
Evaluation of a Contig Spanning the YAC 792t2
BACs 344A17, 346J21, 411M24 and 411M22 contain most of the markers present on the YAC 792t2, that was shown to restore senescence to immortal mammary tumor cell lines. Since they were found to be overlapping by marker content, further analysis was done to determine the extent of this overlap by Southern hybridization. The BAC 344A17 was used as a probe since it contains the largest human DNA insert by PFGE and PCR analysis. This BAC contains all the markers present on BAC 346J21. Southern analysis showed that this BAC, 344A17, hybridized only with the BACs from the SEN 16 locus and not with the other BACs from the neighboring region ( Figure 2 ).
CONCLUSIONS
Using an unique functional-positional strategy devised to identify and clone senescence genes, my research implicated a role for human chromosome 16 in restoring cellular senescence to immortal breast and ovarian tumor cells. The gene(s) inducing senescence was further localized to
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Deepthi E. Redd) DAMD17-96-1-60. chromosome 16q24.3 by transferring fragments of the long arm of human chromosome 16 containing the selectable marker, gpt, and analyzing the microcell hybrids for human chromosome 16 specific markers. A YAC contig was assembled across the 3-7 cM consensus deletion region. A 360 kb YAC from this deleted region was further shown to induce senescence to immortal breast and ovarian tumor cells.
This report describes efforts to further map the senescence gene, SEN 16. A BAC contig was created across the consensus deletion region and the 360 kB YAC, 792t2. Five BACs, 344A17, 344B17, 346J21, 411M24 and 411M24 were found to span the YAC 792t2. The senescence gene is expected to be present on one or more of these BACs. Experiments are in progress to retrofit these BACs with a selectable marker, neo, and to identify a BAC(s) that restore senescence to immortal breast tumor cell lines.
Introduction of SEN 16 complements a common, if not universal defect in human and rat mammary tumor cells, as well as in other tumor cells. Elucidation of the role of SEN 16 in immortalization and malignant transformation await cloning and sequencing of this gene. involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chrom. 2 3 4 5 6 7 8 9 10 11 12 13 14 
KEY RESEARCH ACCOMPLISHMENTS
Transfer of intact, normal human chromosome 16 restores senescence to immortal human and rat mammary tumor cells, and, to immortal rat ovarian tumor cell lines Transfer of normal, fragments of human chromosome 16q also restore senescence to immortal human and rat mammary tumor cells, and , to immortal rat ovarian tumor cell lines. Senescence gene, SEN 16, is thus localized to 16q23-qter.
PCR analysis of rat revertant clones maps SEN 16 to a 3-7 cM region at 16q24.3
A partial YAC contig spanning the 3-7 cM consensus deletion region was assembled. YACs were retrofitted with a selectable marker, neo. Transfer of YACs into mammalian cells further localized SEN 16 to a 360 kb YAC, 792t2.
A BAC contig was assembled spanning the consensus deletion region and he 360 kb YAC.
SEN 16 mapped to a small genomic region (<200 kb) at 16q24.3 using a unique functional-positional cloning approach.
Introduction
Normal diploid mammalian cells undergo replicative senescence after a finite number of population doublings . In contrast, cells cultured from many tumors can either proliferate indefinitely or have an increased proliferative lifespan (Stamps et al., 1992) . Senescent cells are incapable of DNA replication but remain metabolically active for an extended period of time and are resistant to apoptosis Wang, 1995) .
Cellular senescence is a genetically programmed process, expressed as a dominant phenotype over indefinite proliferation in hybrids between normal and immortal cells (Bunn and Tarrant, 1980; Pereira-Smith and Smith, 1983) . By somatic cell hybrid analysis among a large number of immortal cell lines of diverse origin, four complementation groups have been identified for indefinite proliferation (Pereira-Smith and Smith, 1988) .
Spontaneous immortalization can occur in cultured rodent cells (Barrett and Ts'o, 1978) but has not been observed in human cells. Transformation of normal human cells with oncogenic DNA viruses extends the proliferative lifespan but such cells eventually enter a state of irreversible growth arrest (Gotoh et al., 1979; Neufield et al. 1987) . However, human cells transformed with oncogenic DNA viruses can give rise to immortal clones at a low frequency (Huschtscha and Holliday, 1983; Neufield et al., 1987; Shay and Wright, 1989) . The immortalization of cells following transformation with DNA viruses has been shown to involve alterations in the cell genome (Neufield et al., 1987; Goolsby et al., 1991; Hubbard-Smith et al., 1992; Steenbergcn ci al., 1998) . Thus, acquisition of indefinite proliferation is a multistep process and requires inactivation of cellular genes in addition to the function of proteins encoded by the viral genome Hubbard-Smith et al., 1992) . Cellular senescence has been postulated as a mechanism of tumor suppression, and immortalization appears to be an important step in tumor progression (O'Brien et al., 1986; Sager, 1989; Yeager et al., 1997) . Suggestive evidence for the role of senescence in protection against tumorigenesis comes from the comparison of normal and pre-neoplastic immortal mammary epithelial cells, transplanted into cleared mammary fat pads (Daniel et al, 1983) . The proliferation of normal mammary cells declines after 5-6 serial passages ending in a state of senescence, whereas pre-neoplastic immortal cells can be passaged indefinitely and eventually give rise to neoplastic growth (reviewed in Medina, 1996; Daniel et al., 1983 , Medina et al., 1993 . Similarly, in vitro cultures of myoinvasive transitional cell carcinomas (TCC) of bladder give rise to immortal cell lines, while superficial non invasive TCC cells, like normal human uroepithelial cells, undergo senescence after a limited number of population doublings (Yeager et al., 1997) . These studies suggest that escape from senescence is essential for neoplastic expansion and may accelerate tumor progression by increasing the opportunity for additional mutations in proliferating cell populations.
Functional complementation by microcell mediated chromosome transfer into tumor cells has been used to identify chromosomes carrying genes which suppress in vitro cell growth (reviewed in , tumorigenicity and/or metastasis in nude mice (Goyette et al, 1992; Negrini et al., 1994; Welch et al., 1994) or restore cellular senescence (reviewed in Oshimura and Barrett, 1997) . Using this approach, putative cell senescence genes have been identified on chromosomes 1, 2, 3, 4, 6, 7, 17, 18 and X (Hensler et al., 1994; Uejima et al., 1995; Rimessi et al, 1994; Ning et al., 1991; Gualandi et al., 1994; Sandhu et al., 1994; Sandhu et al., 1996; Ogata et al., 1993; Yamada et al., 1990; Wang et al, 1992 ; and our unpublished results). Conceptually these studies imply that a single gene, present on a donor chromosome, confers senescence in recipient cells. Reversion to indefinite proliferation can occur due to Dccplhi I-. Rctkly DAMDI7-96-l-6()5y inactivation of this gene by mutation or deletion of the senescence gene (Sandhu et al., 1996) . In this paper we report the identification of a gene (SEN16) on chromosome 16 that restores senescence in human and rat mammary tumor cells. We have applied a deletion mapping approach to define the position of the gene within a genetic interval of 3-7cM at 16q24.3.
Results
Chromosome Transfer into Tumor Cell Lines
Normal human chromosomes 7, 13 or 16 as well as chromosome fragments 16q22-qter or 16q23-qter, each tagged with gpt, were transferred individually into human and rat mammary tumor cell lines via microcell fusion. Microcell hybrids were recovered in MX selection medium with an average frequency of 1 per 10 6 recipient cells.
Chromosome transfer colonies were maintained in MX medium and examined at regular intervals to assess colony and cell morphology and growth characteristics. Based on these criteria, microcell hybrid clones fell into two distinct classes. 1) Immortal colonies were indistinguishable from the parental tumor cells, which proliferate indefinitely with a doubling time of 15-30h. 2) Senescent colonies consisted of enlarged flattened vacuolated cells, with an initial doubling time of 72-96h that increased progressively until complete growth arrest after 6-8 weeks (Table 1 , Fig.l) .
At this stage, each senescent colony contained between 500 and 2000 cells which remained attached to the surface in a nondividing state for an additional 1-2 months.
Following the transfer of chromosome 16, 16q22-qter or 16q23-qter, a total of 56 independent microcell hybrid colonies were obtained in two human breast tumor cell lines (MCF.7
Deepthi E. Reddy DAMD17-96- and SKBR-3), while 99 colonies were recovered in two rat mammary tumor cell lines (NMU and LA7) ( Table 1 ). All microcell hybrid clones carrying chromosome 16, 16q22-qter or 16q23-qter displayed the senescent phenotype (Table 1, Fig. 1 ). In contrast, the introduction of chromosome 7 into LA7 or chromosome 13 into MCF.7 and NMU cells did not affect the morphology or proliferation potential of the recepient cell lines (Table 1, Fig. 1 ). These results show that chromosome 16 carries a gene, located in the region 16q23-qter, that induces senescence in human as well as in rat mammary tumor cells.
Analysis for The Presence of Donor Chromosome in Senescent Microcell Hybrids
DNA prepared from senescent chromosome transfer clones was analyzed by PCR for the presence of chromosome 16 specific markers, in parallel with DNA from donor and recipient cells.
Since donor chromosomes are tagged with gp_L retention of gp_t_ in all microcell hybrids was confirmed by PCR ( Fig.2A) . Microcell hybrids of MCF.7 and SKBR-3 cells were examined for the presence of donor chromosome 16 alleles for 15 polymorphic microsatellite (CA) repeat markers, while colonies of rat cells were analyzed for 89 markers. A typical example of this type of analysis is presented in figure 2 and a list of the markers is given in Material and Methods.
These experiments confirmed that senescent microcell hybrids retained all donor chromosome markers. The presence of the donor chromosome in microcell hybrids of rat cells was also confirmed by cytogenetic analysis by FISH (Fig. 3) .
Reversion to Indefinite Proliferation Concordant with the Segregation of Donor Chromosome
If the donor chromosome is indeed responsible for cell senescence in chromosome transfer 
Localization of the Senescence Gene within a 3-7cM Genetic Interval at 16q24.3
While senescent microcell hybrid colonies were maintained in MX medium, fast growing parental type immortal revertant clones appeared spontaneously in senescent cell populations. Such revertants, which retained the gp_t tag and most of the donor chromosome, must result from inactivation of the senescence gene through mutation or deletion.We isolated 5 and 16 independent MX revertant clones from microcell hybrids of human and rat cells, respectively, containing chromosome 16, 16q22-qteror 16q23-qter.
To facilitate high resolution mapping of the senescence gene, all MX revertant clones were tested by PCR for markers mapped to the region 16q22-qter. As expected, all revertant clones retained the gpt tag. Of the 16 rat revertant clones, 13 (represented by Rev 1 in figure 4 ) retained all 89 markers tested but 3 revertants Rev 2, Rev 3 and Rev 4 (Fig.4) each lost a block of contiguous linked markers. Figure 2 shows representative PCR analysis of 4 markers which are deleted in Rev (Fig. 4) .The consensus deletion is flanked by markers D16S486 and D16S413 (Fig. 4) . According to the latest integrated map of chromosome 16 in genetic databases.
D16S486 and D16S413 are separated by a genetic distance of less than 7cM at 16q24.3 (NCBI database; Doggett et al., 1995; Kozman et al., 1996; Dib et al., 1996) . However, all 21 markers located in the consensus deletion are mapped within a span of 3 cM (Fig.4) . These results show that SEN16 is located within a 3-7 cM genetic interval at 16q24.3.
High resolution mapping of MX revertants of microcell hybrids of MCF.7 and SKBR-3 cells was hindered by the lack of polymorphism between recipient and donor alleles of most available markers. Of the markers listed in figure 4 , only D16S498 and D16S413 were found to be polymorphic between donor and recipient chromosomes. Both of these markers were consistently deleted in all 5 revertant clones derived from senescent microcell hybrids of MCF.7 and SKBR-3 cells. D16S498 is part of the consensus deletion observed in rat revertant clones, while D16S413 is located just outside the consensus deletion (Fig.4) . Thus the available data from microcell hybrids of human breast tumor cells are consistent with the mapping data in rat revertants and support the hypothesis that the same gene restores senescence in all four cell lines. To strengthen this conclusion, a derivative of chromosome 16q23-qter, carrying the mapped deletion in Rev 4, was introduced into MCF.7 cells. As expected, all 4 microcell hybrids obtained in this experiment were identical to the MCF.7 immortal parental tumor cells (data not shown). These results confirmed that the deletion mapped in Rev 4 abolishes the ability of 16q23-qter to restore with the segregation of the donor chromosome, confirmed that restoration of senescence depends on retention of the donor chromosome. In control experiments, human chromosomes 7 or 13 had no effect on the proliferation of same cells.
In the course of these studies, we also developed an effective general strategy for the mapping of cell senescence/tumor suppressor genes. This strategy is based upon the identification of the smallest consensus deletion in the donor chromosome in independent revertant clones that arise in senescent microcell hybrids maintained in the selection medium. In the present study, the shortest shared consensus deletion that abolishes senescence gene activity is flanked by the markers, D16S486 and D16S413 which are separated by a genetic interval of less than 7cM at 16q24.3 (NCBI database). However, markers located in the consensus deletion are mapped within Table 1 ). The reason for this difference is not known but it could reflect a cell line specific effect of other co-transferred genes on chromosome 16.
Although this is the first report of a senescence gene on chromosome 16, the existence of tumor suppressor genes on this chromosome has been predicted from classical studies of loss of heterozygosity (LOH) on different tumors. In addition to breast carcinoma , frequent deletions on 16q have been reported in prostate carcinoma , hepatocellular carcinoma and Wilms tumors . The high incidence of allelic losses on 16q, in multiple tumors, suggest a universal role for gene(s) present on 16q in different cancers . Three regions on 16q, 16q22. 2-16q22.1, 16q23.1-q23.3 and 16q24.3-qter, which show a high incidence of allelic imbalance, have been implicated in pathogenesis of breast cancer CletonJansen et al., 1994; . However, most frequent LOH has been observed at 16q24.3-qter irrespective of the stage of the disease (reviewed in Brenner and Aldej, 1997; Devilee and Cornelisse 1994) , suggesting that allelic imbalance at 16q24.3 may be an early event in the progression of breast cancer.
11 LOH analysis has been useful to identify loci that are deleted in tumor cells. However, it does not differentiate which loci are directly involved in tumor development and which may be lost coincidentally due to genomic instability associated with the malignant state. In contrast, functional complementation can distinguish whether a locus is involved in the suppression of tumorigenicity and/or metastasis in vivo or inhibition of cell growth and/or restoration of senescence in vitro (reviewed in Oshimura and Barrett 1997; Goyette et al., 1992) Our results show that a gene located at 16q24.3 is responsible for limiting the proliferative life span of breast tumor cells.
Several interesting genes, thought to be involved in the regulation of cell growth, have been mapped at 16q24.3. These include the renal dipeptidase gene, DPEP1 (Austruy et al., 1993) , melanocortin stimulating hormone receptor gene, MCIR (Gantz et al., 1994) , breast basic conserved gene, BBC1 (Adams et al., 1992) , adhesion regulatory molecule, CMAR (Pullman and Bodmar, 1992) , a metallopeptidase gene, PRISM1 (Scott et al., 1996) , a gene named PISSLRE (Li et al., 1992 ) and the Fanconi Anaemia group A gene, FAA (Pronk et al., 1995) . All these genes have been located within a 960kb DNA segment mapping between D16S3026 and D16S303 (Whitmore et al., 1998) which is distal to the region deleted in our immortal MX revertants clones.
Thus, we have excluded all these genes as candidates for SEN 16, based upon their map position or their retention in immortal revertants of senescent microcell hybrids.
The fact that SEN 16 had essentially the same effect in four independently derived rat and human tumor cell lines suggests that it complements a common if not universal defect in mammary tumor cells. Since escape from senescence is considered to be involved in the conversion of nonmalignant tumors to the malignant state, it is probable, that inactivation of SEN 16 may be an essential step during the early stages of tumor progression required for unlimited clonal expansion of the tumor. Direct testing for the role of SEN 16 in the regulation of cell proliferation and mammary tumorigenesis will be possible once the gene is cloned.
Materials and Methods
Cell Lines and Growth Conditions:
Two human breast adenocarcinoma cell lines, SKBR-3 and MCF.7 (American Type Culture Collections, Rockville, MD), and two rat mammary tumor cell lines NMU (American Type Culture Collections), and LA7 (Ehmann et al., 1991) All cell lines were routinely cultured in DF12 medium supplemented with 10-15% fetal bovine serum at 37° C in a 7.5% C0 2 / air atmosphere. The medium for selection and propagation of chromosome transfer clones and donor mouse/human monochromosomal hybrid cell lines contained 25 U^g/ml mycophenolic acid and 70 fi-g/ml xanthine (MX medium).
Microcell Mediated Chromosome Transfer
u Micronuclei formation in donor cells was induced by mitotic arrest with colcemid (0.2ug/ml) for 40 hours and microcells were prepared by zonal centrifugation as previously described (Athwal et al. 1985) . Purified microcells were layered on top of a monolayer of recipient cells (2xl0 6 / 10 cc dish) in the presence of phytohemagglutinin-P (PHA-P, 100ug/ml) and plates were incubated at 37° C for 15 min. The cell fusion was facilitated by the addition 1 ml of PEG 1500 (Boehringer Mannheim) using the standard procedure (Athwal et al., 1985) . In each experiment microcells prepared from approximately 2xl0 7 cells were fused with 4-5xl0 6 recipient cells. After fusion, cells were cultured in non-selective medium for 24 hours, and then transferred to MX medium. Microcell hybrid colonies, observed during the ensuing period of 3-4 weeks, were either isolated individually or maintained in the same plates in MX medium.
Analysis of Chromosome Transfer Clones
Chromosome transfer colonies were maintained in MX medium and examined for cellular and colony morphology and photographed at regular intervals. The population doubling time in each colony was determined by counting cells, either under the microscope or in photomicrographs. The presence or absence of the donor chromosome in each clone and (he location of deletions in the donor chromosome were determined by PCR analysis for donor chromosome specific DNA markers. All primer pairs for PCR amplification were either purchased from Research Genetics (Huntsville,AL) or synthesized commercially. Chromosome 16 specific markers used for mapping included: D16S303, 305, 402, 413, 422, 449, 476, 486, 488, 498, 520, 686, 2621, 2625, 2693, 2727, 2750, 2751, 2772, 2733, 2784, 2790, 2801, 2807, 2866, u Deepthi E. Reddy DAMD17-96-1-6059 3026, 3028, 3048, 3037, 3061, 3063, 3077, 3121, 3205 and 3318; WI-1435, 1728, 3181, 3217, 3661, 6143, 7624, 8422, 10279, 10391, 11335, 11775, 12410, 13072, 15502, 15838, 16080, 16844, 16952, 17119, 17574, 18220 and 18377; SHGC2485, 2489, 3238 and 11987; StSG 2389 StSG , 2700 SGC30619, 30711, 31012, 32044 , 33145, 33289 and 36958;  KIAA0182 and 0233; TIGR-A00B17, A001Y24, A00Y26, A008S19, A00Q31 and A002Y45; D42053, D29571, D29107; U06088; X6563; EST00889; PRSM1 and BBC1.
Microcell hybrids of human cells were analyzed for polymorphic dinucleotide repeat markers (Dib et al., 1996) to distinguish among donor and recipient cell chromosomes. Briefly, the CA strand primers were end labeled with 32 P and used in PCR reactions as described (May and Weber, 1989) . PCR products from chromosome transfer clones and parental cell lines were compared by separation in 6% polyacrylamide denaturing gels to distinguish donor and recipient alleles.
In microcell hybrids derived from rat recipient cells, human donor chromosome markers were detected by conventional PCR amplification. The PCR products were resolved on 2% agarose gels and visualized after staining with ethidium bromide. PCR amplifications were performed in a 25|Xl reaction volume containing PCR buffer, 200 uJvl dNTPs, 2mM MgCl 2 and 10 picomoles primer pair, using the conditions as recommended by the primer supplier (Research Genetics, Huntsville AL).
The gpt gene present on the donor chromosome was detected by PCR amplification of a 700 bp segment using GPT1 and GPT2 primers as described (Kaur and Athwal, 1993) .
Cytogenetic analysis
Metaphase spreads of microcell hybrids were prepared by standard methods and analyzed 15 by Fluorescent In Situ Hybridization (FISH). A biotinylated probe prepared from total human DNA was hybridized to metaphase spreads and was detected by staining with fluorescein labeled streptavidin (Oncor, Gaithersburg, MD) as recommended by the supplier. 
